Aptevo Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 5, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 5, 2024

APVO$1.13-8.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Stockholders’ Equity

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

Additional · Total
Common Stock · Paid-In · Accumulated · Stockholders'
	Shares	Amount	Capital	Deficit	Equity
Balance at December 31, 2021	4,898,143	$47	$215,232	$(214,063)	$1,216
Common stock issued upon vesting of restricted stock units and exercised stock options	16,810	—	(5)	—	(5)
Commitment shares issued pursuant to Lincoln Park Purchase Agreement	99,276	—	—	—	—
Proceeds from issuance of common stock	1,452,065	1	6,933	—	6,934
Stock-based compensation	—	—	1,802	—	1,802
Net income for the period	—	—	—	8,027	8,027
Balance at December 31, 2022	6,466,294	$48	$223,962	$(206,036)	$17,974
Common stock issued upon vesting of restricted stock units and exercised stock options	96,804	—	(10)	—	(10)
Proceeds from issuance of common stock	9,095,430	9	6,419	—	6,428
Proceeds from warrant inducement, net of issuance cost(1)	3,809,652	4	963	—	967
Warrant modification - incremental fair value	—	—	2,080	—	2,080
Stock-based compensation	—	—	2,193	—	2,193
Net (loss) for the period	—	—	—	(17,411)	(17,411)
Balance at December 31, 2023	19,468,180	$61	$235,607	$(223,447)	$12,221

(1) Includes gross proceeds of $3.3 million less issuance costs of $2.3 million, which includes $2.1 million warrant modification incremental fair value.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.